Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel-Reference-Cited by-同舟云学术

Risk sharing or risk shifting? On the development of patient access schemes in the process of updating the national list of health services in Israel

Published:2019-11-02 Issue:6 Volume:19 Page:749-753
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Triki Noa¹,Ash Nachman²³,Porath Avi⁴,Birnbaum Yair⁵,Greenberg Dan⁶,Hammerman Ariel⁷

Affiliation:

1. Department of Health Technology Policy, Maccabi Healthcare Services, Tel-Aviv, Israel

2. Medical Division, Maccabi Healthcare Services, Tel-Aviv, Israel

3. The Department of Health Systems Management, Ariel University, Ariel, Israel

4. Department of Public Health, School of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er-Sheva, Israel

5. Clalit Health Services Headquarters, Tel-Aviv, Israel

6. Department of Health Systems Management, School of Public Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Be'er-Sheva, Israel

7. Department of Pharmaceutical Technology Assessment, Clalit Health Services Headquarters, Tel-Aviv, Israel

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2019.1702525

Reference11 articles.

1. Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions

2. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

3. Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Priority setting for health technology adoption at the national level: Lessons learned over 25 years’ experience;International Journal of Technology Assessment in Health Care;2023

2. Social pharmaceutical innovation and alternative forms of research, development and deployment for drugs for rare diseases;Orphanet Journal of Rare Diseases;2022-09-05

3. How Managed Entry Agreements can improve allocation in the public health system: a mechanism design approach;The European Journal of Health Economics;2021-03-23